Duchenne Muscular Dystrophy

FDA Approves Novel Corticosteroid Treatment Option for DMD Patients
BioSpace
Fri, 10/27/23 - 11:47 am
Santhera Pharmaceuticals
Catalyst Pharmaceuticals
Agamree
FDA
DMD
Duchenne Muscular Dystrophy
Santhera closes on first approval for DMD drug vamorolone
Pharmaphorum
Fri, 10/13/23 - 10:23 am
Santhera
Duchenne Muscular Dystrophy
DMD
vamorolone
EMA
Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study
BioSpace
Thu, 09/28/23 - 10:33 am
NEJM
clinical trials
Duchenne Muscular Dystrophy
patient deaths
Astellas
Pfizer
FibroGen fails again in DMD, continuing rotten run of phase 3 flops
Fierce Biotech
Wed, 08/30/23 - 10:09 am
FibroGen
Duchenne Muscular Dystrophy
clinical trials
pamrevlumab
Sarepta offers early look at closely watched gene therapy launch
BioPharma Dive
Thu, 08/3/23 - 11:19 am
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Elevidys
drug launches
Sarepta prices Duchenne gene therapy at $3.2M
BioPharma Dive
Fri, 06/23/23 - 09:44 am
Sarepta Therapeutics
drug pricing
DMD
Duchenne Muscular Dystrophy
Elevidys
FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy
BioSpace
Thu, 06/22/23 - 10:51 pm
Sarepta Therapeutics
DMD
Duchenne Muscular Dystrophy
FDA
Elevidys
gene therapy
FibroGen’s Duchenne drug misses mark in first large trial
BioPharma Dive
Wed, 06/7/23 - 09:29 pm
FibroGen
clinical trials
Duchenne Muscular Dystrophy
pamrevlumab
FDA delays decision on Duchenne gene therapy and considers narrower approval
BioPharma Dive
Wed, 05/24/23 - 11:21 am
Sarepta Therapeutics
FDA
DMD
Duchenne Muscular Dystrophy
gene therapy
Sarepta Enters Uncharted Territory with Adcomm Approval
BioSpace
Mon, 05/22/23 - 10:22 am
Sarepta Therapeutics
SRP-9001
DMD
Duchenne Muscular Dystrophy
FDA
gene therapy
FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy
Fierce Biotech
Mon, 05/15/23 - 11:18 am
Sarepta Therapeutics
FDA
DMD
gene therapy
Duchenne Muscular Dystrophy
FDA reviewers flag concerns over Sarepta's gene therapy for DMD
Yahoo/Reuters
Wed, 05/10/23 - 10:08 am
Sarepta Therapeutics
FDA
DMD
Duchenne Muscular Dystrophy
gene therapy
Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm
Fierce Biotech
Wed, 05/3/23 - 11:39 am
Sarepta Therapeutics
FDA
SRP-9001
DMD
Duchenne Muscular Dystrophy
Go or no go? Sarepta’s gene therapy faces scrutiny
EP Vantage
Thu, 04/27/23 - 10:29 am
Sarepta Therapeutics
gene therapy
SRP-9001
Roche
DMD
Duchenne Muscular Dystrophy
Sarepta shares drop as report says FDA almost rejected under-review gene therapy
Yahoo/Reuters
Fri, 04/14/23 - 10:16 am
Sarepta Therapeutics
FDA
gene therapy
DMD
Duchenne Muscular Dystrophy
Chasing Pfizer and Roche, Regenxbio benefits from FDA boost for DMD gene therapy
Fierce Biotech
Tue, 04/11/23 - 11:32 am
Regenxbio
adeno-associated viruses
Duchenne Muscular Dystrophy
FDA
5 FDA decisions to watch in the second quarter
BioPharma Dive
Mon, 04/3/23 - 11:06 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Vertex flexes its dealmaking muscle
EP Vantage
Mon, 03/27/23 - 10:07 am
Vertex Pharmaceuticals
Entrada Therapeutics
Tevard Biosciences
Duchenne Muscular Dystrophy
FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy
BioSpace
Fri, 03/17/23 - 10:13 am
FDA
Sarepta Therapeutics
DMD
gene therapy
Duchenne Muscular Dystrophy
SRP-9001
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
Thu, 03/16/23 - 09:49 am
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone

Pages